News
Novo to part ways with longtime CEO Lars Fruergaard Jørgensen, citing weight of market pressures
It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. | Under a mutual agreement with Novo Nordisk's board of directors,
In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...
Barchart on MSN12h
Is Novo Nordisk Stock a Buy, Sell, or Hold as CEO Lars Fruergaard Jørgensen Resigns?Novo Nordisk (NVO) is in focus on Friday after its long-time chief executive Lars Fruergaard Jørgensen announced his ...
Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he ...
Novo Nordisk A/S’s surprise decision to replace Chief Executive Officer Lars Fruergaard Jorgensen has triggered a race to ...
Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...
In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...
Danish maker of obesity drugs to replace Lars Fruergaard Jørgensen, saying new leadership is needed as shares slump 50% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback